Takeda Pharmaceutical (NYSE:TAK) Shares Gap Up – Time to Buy?

Shares of Takeda Pharmaceutical Co. (NYSE:TAK) gapped up prior to trading on Tuesday . The stock had previously closed at $17.38, but opened at $17.86. Takeda Pharmaceutical shares last traded at $18.1150, with a volume of 1,005,861 shares.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The firm has a market cap of $57.91 billion, a P/E ratio of 53.19 and a beta of -0.08. The firm has a 50-day simple moving average of $16.60 and a 200-day simple moving average of $17.15.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.30. The business had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. As a group, analysts forecast that Takeda Pharmaceutical Co. will post 1.5 EPS for the current year.

Insider Buying and Selling

In other Takeda Pharmaceutical news, insider Giles Richard Platford sold 31,083 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $531,519.30. Following the completion of the transaction, the insider directly owned 315,838 shares in the company, valued at approximately $5,400,829.80. The trade was a 8.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Natalie Anne Marie Furney sold 30,868 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $527,842.80. Following the sale, the general counsel directly owned 204,298 shares of the company’s stock, valued at approximately $3,493,495.80. The trade was a 13.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 444,100 shares of company stock valued at $7,594,110 over the last three months. Corporate insiders own 0.04% of the company’s stock.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of large investors have recently made changes to their positions in TAK. Valeo Financial Advisors LLC acquired a new position in Takeda Pharmaceutical during the 2nd quarter valued at about $163,000. GAMMA Investing LLC raised its position in Takeda Pharmaceutical by 10.7% during the 2nd quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock worth $222,000 after buying an additional 1,338 shares during the last quarter. Versant Capital Management Inc lifted its stake in Takeda Pharmaceutical by 10.8% during the 2nd quarter. Versant Capital Management Inc now owns 42,686 shares of the company’s stock valued at $684,000 after acquiring an additional 4,169 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical by 10.5% in the 1st quarter. Parallel Advisors LLC now owns 24,651 shares of the company’s stock valued at $457,000 after acquiring an additional 2,343 shares during the last quarter. Finally, Glenmede Trust Co. NA boosted its holdings in shares of Takeda Pharmaceutical by 9.6% in the 1st quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company’s stock valued at $559,000 after acquiring an additional 2,640 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.